Literature DB >> 33756016

Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: A cross-sectional study.

Lukas Ochsner Ridder1, Torben Harsløf1, Tanja Sikjaer1, Line Underbjerg1, Lars Rejnmark1,2.   

Abstract

OBJECTIVE: Hypercalciuria, impaired kidney function and renal calcifications are common in chronic hypoparathyroidism (HypoPT). We aimed to study associations between indices of known importance to the kidney in HypoPT by hypothesizing adverse effects of hypercalciuria on renal outcomes.
DESIGN: We used cross-sectional design. PATIENTS: We identified all patients followed for chronic HypoPT at our department and who had been examined by a 24-h urine collection for measurement of renal calcium excretion (24 h U-Ca). MEASUREMENTS: By chart review, we identified additional biochemistry measured in close connection with the collection of urine, as well as demographic, treatments and anthropometrics.
RESULTS: The 166 included patients (79.5% females) had a high prevalence of hypercalciuria (65.7%). In multiple adjusted analyses, hypercalciuria was in an independent manner inversely associated with (residual) levels of plasma PTH and positively associated with levels of 1,25-dihydroxyvitamin D and ionized calcium as well as 24 h U-phosphate, gender, and etiology (surgical vs. non-surgical). Overall, this model explained 54% (p < .001) of the variation in the presence of hypercalciuria. Chronic kidney disease stage three or above was present in 18.3% of the patients, and 42.6% of the 54 patients examined by renal imaging had renal calcifications. However, neither renal function nor renal calcifications were associated with 24 h U-Ca.
CONCLUSIONS: Hypercalciuria, impaired renal function and renal calcifications are common in hypoparathyroidism. Hypercalciuria is to a large extent explained by indices of known physiological importance to 24 h U-Ca. However, in the present study, a high renal calcium excretion did not explain renal impairment or kidney calcifications.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  alfacalcidol; calcium; hypoparathyroidism; parathyroid hormone

Year:  2021        PMID: 33756016     DOI: 10.1111/cen.14470

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders.

Authors:  Jens Bollerslev; Lars Rejnmark; Alexandra Zahn; Ansgar Heck; N M Appelman-Dijkstra; Luis Cardoso; Fadil M Hannan; Filomena Cetani; Tanja Sikjær; Anna Maria Formenti; Sigridur Björnsdottir; Camilla Schalin-Jantti; Zhanna Belaya; Fraser Wilson Gibb; Bruno Lapauw; Karin Amrein; Corinna Wicke; Corinna Grasemann; Michael Krebs; Eeva M Ryhänen; Ozer Makay; Salvatore Minisola; Sebastien Gaujoux; Jean-Philippe Bertocchio; Zaki K Hassan-Smith; Agnès Linglart; Elizabeth M Winter; Martina Kollmann; Hans-Georg Zmierczak; Elena Tsourdi; Stefan Pilz; Heide Siggelkow; Neil J Gittoes; Claudio Marcocci; Peter Kamenicky
Journal:  Eur J Endocrinol       Date:  2022-01-13       Impact factor: 6.664

Review 2.  Phosphate Metabolism and Pathophysiology in Parathyroid Disorders and Endocrine Tumors.

Authors:  Guido Zavatta; Paola Altieri; Giulia Vandi; Valentina Vicennati; Uberto Pagotto; Fabio Vescini
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

3.  Kidney Complications and Hospitalization in Patients With Chronic Hypoparathyroidism: A Cohort Study in Sweden.

Authors:  Oskar Swartling; Marie Evans; Tim Spelman; Wafa Kamal; Olle Kämpe; Michael Mannstadt; Ylva Trolle Lagerros; Sigridur Björnsdottir
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.